Signaling protein could be the target that stops heart failure in its tracks

human heart
Congestive heart failure gets progressively worse, killing nearly half of all patients within five years after diagnosis.

There is no cure for heart failure, but scientists at Nagoya University have identified a protein on the surface of heart cells that could be targeted to stop the condition from getting worse.

Heart failure, in which the heart is unable to pump enough blood to support the body, can be caused by a number of conditions, including congenital heart defects and a past heart attack. The heart tries to compensate by growing larger, developing more muscle mass or pumping faster, but the condition grows progressively worse until these stopgaps no longer work.

Physicians usually advise patients to embrace lifestyle changes and prescribe drugs such as beta blockers. Medical devices, including implantable cardioverter defibrillators, are also widely used. But these measures cannot reverse the damage that's already done.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

The Nagoya team found that heart cells express the signaling protein, corticotropin-releasing hormone receptor 2 (Crhr2), on their surface, according to a press release. Crhr2 is a G protein-coupled receptor: It detects molecules outside cells and activates pathways inside the cell, which leads to a cellular response.

The researchers discovered that mice with heart failure had elevated levels of Crhr2. They also found that human patients and mice with chronic heart failure had high levels of the protein urocortin2 (Ucn2) in their blood.

They treated mice with Ucn2 and noticed that otherwise healthy mice with Crhr2 lost cardiac function, while mice that lacked the signaling protein were resistant to developing heart failure. A Crhr2 inhibitor delivered after the heart sustained damage preserved heart function in mice.

While current heart failure treatments focus on preserving function, about half of all people who develop heart failure will die within five years of diagnosis, according to the CDC. That's why many scientists are working to improve upon today's treatments.

“Our results suggest that constitutive Crhr2 activation causes cardiac dysfunction and that Crhr2 blockade could be a promising therapeutic strategy for patients with chronic heart failure,” said Mikito Takefuji of Nagoya University Medical School in the statement.

Suggested Articles

Philips is cementing its commitment to becoming a healthcare technology provider, with plans to split off or sell its consumer appliances division.

Joe Jimenez has (another) new gig. The ex-Novartis boss joined the board of Century Therapeutics, a startup working on off-the-shelf cell therapies.

As Pfizer posts its full-year financials today, as usual it’s also sneaked in several dropped projects from its pipeline.